NanoVision Announces Strategic Research Collaborations with Top Chinese Hospitals and Universities to Advance Clinical Applications of World’s First Whole-Body Multi-Source Static CT

On May 14, during the CMEF conference, Nanovision successfully held the kickoff meeting for scientific research collaboration on static CT, officially announcing research partnerships with several top-tier hospitals and leading universities in China regarding the world’s first whole-body medical multi-source static CT.

Professor Huang Gang, President-Elect of the Nuclear Medicine Physicians Branch of the Chinese Medical Doctor Association, President of the Asia-Pacific Federation of Nuclear Medicine and Biology, and Chairman of the Health Management Specialty Committee of the Shanghai Medical Association，Professor Feng Xiaoyuan, Lifetime Professor at Huashan Hospital Affiliated to Fudan University, Honorary Chairman of the 15th Committee of Radiology of the Chinese Medical Association, Chairman of the Shanghai Society of Biomedical Engineering, and Honorary Editor-in-Chief of the Chinese Journal of Radiology，Professor Ye Jianding, Honorary Director of the Department of Radiology at Shanghai Chest Hospital; former member of the Cardiothoracic Professional Committee of the Chinese Medical Doctor Association’s Radiology Branch; member of the Radiology Society of the Shanghai Medical Association; and leader of the Cardiothoracic Specialist Group.Attended the launch ceremony.

At the launch ceremony, Professor Feng Xiaoyuan spoke highly of Nanovision’s globally pioneering multi-source static CT system for whole-body medical imaging, the “Compound Eye 24.” He stated, “Nanovision’s Compound Eye 24 Static CT has achieved independent innovation and full localization, from front-end design to back-end manufacturing. As a result, it faces no “chokehold” risks in core technologies, manufacturing processes, or supply chains. This aligns with the major trend in the development of domestically produced medical devices, with Nanovision currently leading the way.”

Meanwhile, Professor Feng Xiaoyuan expressed strong expectations for the future development of static CT. “Static CT is transforming CT diagnosis from simple morphological assessment to a combination of morphological and biological diagnosis, and further advancing toward molecular diagnosis, marking a major revolution in the history of CT development.”

Led by Nanovision, deep industry-academia-research collaboration jointly explores technological and application innovations in static CT for ultra-high-resolution, near-mesoscopic imaging, enabling earlier detection of smaller lesions and introducing new workflows and standards for clinical disease screening, diagnosis, and treatment.

It is precisely the technological leadership of Nanovision’s static CT products that grants them greater scientific research value.

Nanovision’s Fovea 24 is the world’s first whole-body medical multi-source static CT scanner. It features a dual-ring structure composed of 64 photon-counting detector arrays and 24 X-ray source arrays. Since the X-ray tubes and detectors do not rotate during scanning, there is no motion blur, significantly improving temporal and spatial resolution. This system achieves a voxel resolution 64 times superior to that of conventional spiral CT scanners and offers multi-energy spectral imaging capabilities.The Fuyan 24 static CT has achieved a scan slice thickness of 165 μm, approaching the 100-μm mesoscopic imaging threshold widely recognized by experts.

Nanovision’s head offered a layman’s explanation: “While traditional spiral CT reflects the average value of a given image region, static CT, with its higher resolution, can reveal more valuable information and avoid the loss of accuracy caused by averaging.”

Compound Eye 24 is expected to be approved next year., thereby establishing a moat for Nanovision in terms of time and technological iteration. As the world’s first product of its kind, the Compound Eye 24 has no established development path to follow; it requires continuous expansion into new clinical application areas to explore the tangible value that innovative static CT technology brings to clinical practice. This process necessitates collaboration among multiple stakeholders, including manufacturers, clinicians, and research institutions.

Prior to the official commercial launch of its static CT products, Nanovision has actively pursued scientific research collaborations, holding promising prospects forContinuously optimize product design based on clinical application and feedback. MeanwhileAchieve breakthroughs in challenging clinical diagnosis and treatment, and accumulate more robust clinical evidence. FurthermoreStatic CT can also define its areas of advantage in clinical applications, focusing on target patients., laying the foundation for future market promotion.

This is a win-win situation for all parties involved. Through scientific research collaboration, the effectiveness and innovativeness of the world’s first whole-body medical multi-source static CT product can be further validated.For clinical practice, it facilitates the exploration of disease progression cycles and promotes the development of new diagnostic and therapeutic standards.；For universities, it is conducive to carrying out scientific research and innovation.. Ultimately, these research findings will contribute to the full-cycle management of diseases, thereby benefiting more patients.

As the world’s first whole-body multi-source static CT scanner for medical use, the Fuyan-24 has emerged as a novel clinical imaging modality, offering advantages such as ultra-high resolution, large-matrix imaging (2048×2048), and low radiation dose, thereby facilitating ultra-early disease screening and more precise diagnosis. With continuous technological iterations and upgrades, static CT will increasingly enable the expansion of CT imaging from organ- and tissue-level visualization to cellular-level and comprehensive functional imaging.

The “Healthy China 2030” Planning Outline proposes strengthening health management across the entire life cycle, while the clinical level also emphasizes early screening, early diagnosis, and early treatment of diseases. Imaging examinations are crucial for disease management, as intuitive imaging can be used to assess lesion changes and disease progression. In clinical practice, physicians select imaging modalities based on the specific characteristics of the disease, with factors such as equipment resolution, safety, and cost taken into consideration.

Currently, the imaging modalities commonly used in clinical practice include CT, MRI, and X-ray. X-ray examination is low-cost but offers limited image clarity, making it primarily suitable for initial disease screening. MRI provides high tissue resolution and is radiation-free; however, it involves longer scan times, is sensitive to patient motion, and incurs higher costs, so it is mainly used for brain tissue imaging. CT features rapid scanning speed and high density resolution, but has limited soft-tissue resolution and involves higher radiation exposure than X-rays, posing certain health risks.

Static CT significantly reduces radiation dose while improving resolution. The Fuyan 24 has already approached mesoscopic imaging, and the company’s next-generation product will truly achieve mesoscopic imaging, enabling tissue- and cellular-level information recognition. It can detect lesions at an earlier stage, providing clinicians with richer details to facilitate ultra-early screening and precise diagnosis of diseases. Moreover, static CT involves low radiation exposure, posing minimal harm to the human body.

Static CT is not merely an iteration of traditional CT; it also addresses issues that conventional imaging examinations cannot resolve.

For instance, in the ultra-early screening of lung cancer: as the most prevalent cancer in China, lung cancer often presents without specific symptoms in its early stages. Many patients are only diagnosed at intermediate or advanced stages, resulting in low five-year survival rates and a substantial economic burden. Therefore, early detection, diagnosis, and treatment of lung cancer are critical.

Currently, the detection of early-stage small pulmonary nodules relies primarily on CT scanning and artificial intelligence-based post-processing. For nodules larger than 5 mm, existing imaging modalities can facilitate direct diagnosis; however, for sub-5-mm micronodules, current imaging techniques cannot effectively differentiate between benign and malignant lesions. Therefore, clinical guidelines recommend regular follow-up. Previous clinical cases have confirmed thatSubtle nodules smaller than 5 mm also carry a risk of malignant progression, and patient compliance with regular follow-up is often low; both overdiagnosis and missed diagnoses can lead to wastage of medical resources.

“Detecting lesions via CT and clearly visualizing them are two entirely different concepts."Clinically, it is necessary to magnify the images of lesions to observe changes in the lesion itself and its surrounding conditions. However, due to insufficient resolution of existing imaging methods, the magnified images are relatively blurry, making it impossible to determine the benign or malignant nature of tiny nodules. Static CT, with its ultra-high resolution, can detect changes in small pulmonary nodules, thereby helping doctors effectively assess whether a nodule is benign or malignant and take corresponding intervention measures."

Taking the early screening and diagnosis of COPD as another example, COPD is one of the four major chronic diseases globally. It is primarily diagnosed through pulmonary function tests; however, these tests lack sensitivity in the early stages.Due to the lungs' robust compensatory capacity, studies have reported that pulmonary function only manifests abnormalities when parenchymal destruction exceeds 20%. Furthermore, given the complexity of pulmonary function testing, COPD has often progressed to the moderate-to-severe stages by the time it is detected, rendering the condition irreversible to treatment.。

The progression of COPD often begins with a subtle lesion. CT measurements not only provide a visual representation of pulmonary pathology but also enable accurate assessment of airway disease. However, this places high demands on the quality of CT images.Static CT, through ultra-high-definition scanning, can detect earlier and more subtle changes in the lungs, enabling physicians to intervene with treatment at an earlier stage and holding the promise of altering the disease spectrum.

In addition to respiratory diseases, the skeletal system is another area where static CT demonstrates significant advantages. China has a high prevalence of osteoporosis; however, most patients are unaware of their condition prior to undergoing bone mineral density testing. Moreover, calcium salt loss typically manifests only after systemic skeletal involvement has progressed to a certain stage.

Osteoporosis can manifest as sparse trabeculae on imaging examinations. Trabeculae are the primary load-bearing structures in the proximal femur; however, conventional spiral CT fails to detect early micro-lesions of the trabeculae. Although MicroCT offers extremely high resolution and is well-suited for bone imaging, its small bore size currently restricts its use to small animal experiments.Static CT offers a novel option for the early detection of trabecular bone lesions, enabling timely clinical intervention to slow or halt bone loss.

Focusing on diseases of the respiratory and skeletal systems, static CT has demonstrated significant application advantages.

Currently, Nanovision has partnered with multiple renowned hospitals and top-tier universities in China to explore the applications of static CT in areas such as pulmonary nodules, COPD, and hepatobiliary diagnosis. Meanwhile, the company is actively advancing the clinical trials of its Compound Eye 24 system and developing next-generation static CT products capable of achieving true mesoscopic imaging.

Higher resolution, greater detail, and enhanced safety have always been the primary goals of clinical imaging examinations. Static CT has achieved further advancements in these areas, with more disease domains yet to be explored.

In the future, Nanovision hopes to establish research collaborations with more top-tier hospitals and specialized universities in China, jointly contributing to the exploration of innovative applications of static CT technology.Leveraging Nanovision’s innovative technologies and industry insights, and combining them with the scientific research capabilities and background resources of its partners, we jointly create new clinical diagnosis and treatment workflows and standards, ultimately benefiting clinical patients.。